Medical journal The Lancet published an article Wednesday that could mold the future of cannabis-derived therapeutics. The piece in question featured results from GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) and Greenwich Biosciences' Phase 3 study of Epidiolex — an oral cannabidiol ...
read more here
Delivered by @can_nab_is
No comments:
Post a Comment